Video
Dr. Chaft on Ongoing Pivotal Trials in EGFR-Mutant NSCLC
Author(s):
In Partnership With:
Jamie E. Chaft, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses pivotal ongoing clinical trials in the landscape of EGFR-mutant non–small cell lung cancer (NSCLC).
Jamie E. Chaft, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses pivotal ongoing clinical trials in the landscape of EGFR-mutant non—small cell lung cancer (NSCLC).
The most anticipated trial is the FLAURA study, which is exploring first-line osimertinib (Tagrisso) versus erlotinib (Tarceva) and gefitinib (Iressa) in patients with EGFR T790M-mutant NSCLC, Chaft explains.
However, the one caveat is that the trial’s primary endpoint is progression-free survival, and researchers question whether osimertinib will demonstrate an overall survival advantage. Furthermore, it is unclear whether they should utilize a first- or second-generation drug after osimertinib or if there will be new drugs available that are specifically targeted at the time of progression on osimertinib.
